The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer
Prostate cancer (PC) is a major health issue in developed countries, with, on the one hand, men suffering from sequelae related to unnecessary treatment of non-lethal PC, and, on the other hand, still dying because of advanced PC that progresses to castration-resistant disease. Systemic treatment is...
Gespeichert in:
| Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2019-03, Vol.79 (4), p.381-400 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 400 |
|---|---|
| container_issue | 4 |
| container_start_page | 381 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 79 |
| creator | Pagliuca, Martina Buonerba, Carlo Fizazi, Karim Di Lorenzo, Giuseppe |
| description | Prostate cancer (PC) is a major health issue in developed countries, with, on the one hand, men suffering from sequelae related to unnecessary treatment of non-lethal PC, and, on the other hand, still dying because of advanced PC that progresses to castration-resistant disease. Systemic treatment is the mainstay of therapy of castration-resistant PC (CRPC). To date, a multitude of systemic agents have been tested and many of these have failed to provide a clinically meaningful benefit in CRPC, while others have been approved by the US Food and Drug Administration and/or the European Medicines Agency, including antiandrogen hormonal drugs (abiraterone, enzalutamide, apalutamide), chemotherapy (docetaxel and cabazitaxel), immunotherapy (Sipuleucel-T), and radiopharmaceutical (Radium-223) agents. In this review, systemic treatments regarded as most likely to have an impact in clinical practice are presented and discussed. In addition to the pivotal clinical studies, selected retrospective and non-randomized clinical trials are also discussed if deemed to have an impact on clinical practice or future research. A comprehensive appraisal of the expanding landscape of systemic therapies for advanced PC is provided from an expert perspective, with a focus on novel classification and diagnostic tools that have been paving the way for the development of precision medicine in PC. |
| doi_str_mv | 10.1007/s40265-019-1060-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2194157430</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2194157430</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-c19f2374f3161c30d5701b2174c5a9ea54e478c97fa74a22aa4c977611cf99a23</originalsourceid><addsrcrecordid>eNp1kMtKAzEUhoMotlYfwI0E3LgZPSeTS7MsxRsUFKzrEDMZHenM1CSt-Pam1AsIrsKffOdP8hFyjHCOAOoicmBSFIC6QJBQiB0yRFQ5aQG7ZAiArJBSqgE5iPF1E7XQ-2RQguKMKT0k8_mLp5frfrFuumf68BGTbxtH58Hb1Pou0Zntqujs0tO6D_TepibvRvrepBc6qda2c76i96GPySZPp5scDslebRfRH32tI_J4dTmf3hSzu-vb6WRWuFKxVDjUNSsVr0uU6EqohAJ8Yqi4E1Z7K7jnauy0qq3iljFreQ5KIrpaa8vKETnb9i5D_7byMZm2ic4vFrbz_SoahpqjULyEjJ7-QV_7Vejy6wxjYgwahJSZwi3l8odi8LVZhqa14cMgmI1ys1VusnKzUW5Enjn5al49tb76mfh2nAG2BWI-6p59-L36_9ZPOxSKNw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2258090566</pqid></control><display><type>article</type><title>The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Pagliuca, Martina ; Buonerba, Carlo ; Fizazi, Karim ; Di Lorenzo, Giuseppe</creator><creatorcontrib>Pagliuca, Martina ; Buonerba, Carlo ; Fizazi, Karim ; Di Lorenzo, Giuseppe</creatorcontrib><description>Prostate cancer (PC) is a major health issue in developed countries, with, on the one hand, men suffering from sequelae related to unnecessary treatment of non-lethal PC, and, on the other hand, still dying because of advanced PC that progresses to castration-resistant disease. Systemic treatment is the mainstay of therapy of castration-resistant PC (CRPC). To date, a multitude of systemic agents have been tested and many of these have failed to provide a clinically meaningful benefit in CRPC, while others have been approved by the US Food and Drug Administration and/or the European Medicines Agency, including antiandrogen hormonal drugs (abiraterone, enzalutamide, apalutamide), chemotherapy (docetaxel and cabazitaxel), immunotherapy (Sipuleucel-T), and radiopharmaceutical (Radium-223) agents. In this review, systemic treatments regarded as most likely to have an impact in clinical practice are presented and discussed. In addition to the pivotal clinical studies, selected retrospective and non-randomized clinical trials are also discussed if deemed to have an impact on clinical practice or future research. A comprehensive appraisal of the expanding landscape of systemic therapies for advanced PC is provided from an expert perspective, with a focus on novel classification and diagnostic tools that have been paving the way for the development of precision medicine in PC.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.1007/s40265-019-1060-5</identifier><identifier>PMID: 30742279</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Androgen Antagonists - therapeutic use ; Androgens ; Androstenes - therapeutic use ; Antineoplastic Agents - therapeutic use ; Antineoplastic Agents, Hormonal - therapeutic use ; Cancer therapies ; Castration ; Chemotherapy ; Clinical medicine ; Clinical trials ; Clinical Trials as Topic ; Complications ; Developed countries ; Diagnostic software ; Diagnostic systems ; Docetaxel - therapeutic use ; FDA approval ; Humans ; Immunotherapy ; Immunotherapy - methods ; Internal Medicine ; Landscape ; Male ; Medical research ; Medical treatment ; Medicine ; Medicine & Public Health ; Metastasis ; Molecular Targeted Therapy ; Pain ; Pharmaceuticals ; Pharmacology/Toxicology ; Pharmacotherapy ; Phenylthiohydantoin - analogs & derivatives ; Phenylthiohydantoin - therapeutic use ; Precision medicine ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Radiochemistry ; Radioisotopes ; Radiopharmaceuticals - therapeutic use ; Radium ; Radium - therapeutic use ; Retrospective Studies ; Review Article ; Taxoids - therapeutic use ; Thiohydantoins - therapeutic use ; Tissue Extracts - therapeutic use</subject><ispartof>Drugs (New York, N.Y.), 2019-03, Vol.79 (4), p.381-400</ispartof><rights>Springer Nature Switzerland AG 2019</rights><rights>Copyright Springer Nature B.V. Mar 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-c19f2374f3161c30d5701b2174c5a9ea54e478c97fa74a22aa4c977611cf99a23</citedby><cites>FETCH-LOGICAL-c372t-c19f2374f3161c30d5701b2174c5a9ea54e478c97fa74a22aa4c977611cf99a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40265-019-1060-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40265-019-1060-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30742279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pagliuca, Martina</creatorcontrib><creatorcontrib>Buonerba, Carlo</creatorcontrib><creatorcontrib>Fizazi, Karim</creatorcontrib><creatorcontrib>Di Lorenzo, Giuseppe</creatorcontrib><title>The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><addtitle>Drugs</addtitle><description>Prostate cancer (PC) is a major health issue in developed countries, with, on the one hand, men suffering from sequelae related to unnecessary treatment of non-lethal PC, and, on the other hand, still dying because of advanced PC that progresses to castration-resistant disease. Systemic treatment is the mainstay of therapy of castration-resistant PC (CRPC). To date, a multitude of systemic agents have been tested and many of these have failed to provide a clinically meaningful benefit in CRPC, while others have been approved by the US Food and Drug Administration and/or the European Medicines Agency, including antiandrogen hormonal drugs (abiraterone, enzalutamide, apalutamide), chemotherapy (docetaxel and cabazitaxel), immunotherapy (Sipuleucel-T), and radiopharmaceutical (Radium-223) agents. In this review, systemic treatments regarded as most likely to have an impact in clinical practice are presented and discussed. In addition to the pivotal clinical studies, selected retrospective and non-randomized clinical trials are also discussed if deemed to have an impact on clinical practice or future research. A comprehensive appraisal of the expanding landscape of systemic therapies for advanced PC is provided from an expert perspective, with a focus on novel classification and diagnostic tools that have been paving the way for the development of precision medicine in PC.</description><subject>Androgen Antagonists - therapeutic use</subject><subject>Androgens</subject><subject>Androstenes - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Cancer therapies</subject><subject>Castration</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Complications</subject><subject>Developed countries</subject><subject>Diagnostic software</subject><subject>Diagnostic systems</subject><subject>Docetaxel - therapeutic use</subject><subject>FDA approval</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Internal Medicine</subject><subject>Landscape</subject><subject>Male</subject><subject>Medical research</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Molecular Targeted Therapy</subject><subject>Pain</subject><subject>Pharmaceuticals</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Phenylthiohydantoin - analogs & derivatives</subject><subject>Phenylthiohydantoin - therapeutic use</subject><subject>Precision medicine</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Radiochemistry</subject><subject>Radioisotopes</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Radium</subject><subject>Radium - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Review Article</subject><subject>Taxoids - therapeutic use</subject><subject>Thiohydantoins - therapeutic use</subject><subject>Tissue Extracts - therapeutic use</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kMtKAzEUhoMotlYfwI0E3LgZPSeTS7MsxRsUFKzrEDMZHenM1CSt-Pam1AsIrsKffOdP8hFyjHCOAOoicmBSFIC6QJBQiB0yRFQ5aQG7ZAiArJBSqgE5iPF1E7XQ-2RQguKMKT0k8_mLp5frfrFuumf68BGTbxtH58Hb1Pou0Zntqujs0tO6D_TepibvRvrepBc6qda2c76i96GPySZPp5scDslebRfRH32tI_J4dTmf3hSzu-vb6WRWuFKxVDjUNSsVr0uU6EqohAJ8Yqi4E1Z7K7jnauy0qq3iljFreQ5KIrpaa8vKETnb9i5D_7byMZm2ic4vFrbz_SoahpqjULyEjJ7-QV_7Vejy6wxjYgwahJSZwi3l8odi8LVZhqa14cMgmI1ys1VusnKzUW5Enjn5al49tb76mfh2nAG2BWI-6p59-L36_9ZPOxSKNw</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Pagliuca, Martina</creator><creator>Buonerba, Carlo</creator><creator>Fizazi, Karim</creator><creator>Di Lorenzo, Giuseppe</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190301</creationdate><title>The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer</title><author>Pagliuca, Martina ; Buonerba, Carlo ; Fizazi, Karim ; Di Lorenzo, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-c19f2374f3161c30d5701b2174c5a9ea54e478c97fa74a22aa4c977611cf99a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Androgen Antagonists - therapeutic use</topic><topic>Androgens</topic><topic>Androstenes - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Cancer therapies</topic><topic>Castration</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Complications</topic><topic>Developed countries</topic><topic>Diagnostic software</topic><topic>Diagnostic systems</topic><topic>Docetaxel - therapeutic use</topic><topic>FDA approval</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Internal Medicine</topic><topic>Landscape</topic><topic>Male</topic><topic>Medical research</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Molecular Targeted Therapy</topic><topic>Pain</topic><topic>Pharmaceuticals</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Phenylthiohydantoin - analogs & derivatives</topic><topic>Phenylthiohydantoin - therapeutic use</topic><topic>Precision medicine</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Radiochemistry</topic><topic>Radioisotopes</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Radium</topic><topic>Radium - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Review Article</topic><topic>Taxoids - therapeutic use</topic><topic>Thiohydantoins - therapeutic use</topic><topic>Tissue Extracts - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pagliuca, Martina</creatorcontrib><creatorcontrib>Buonerba, Carlo</creatorcontrib><creatorcontrib>Fizazi, Karim</creatorcontrib><creatorcontrib>Di Lorenzo, Giuseppe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pagliuca, Martina</au><au>Buonerba, Carlo</au><au>Fizazi, Karim</au><au>Di Lorenzo, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><stitle>Drugs</stitle><addtitle>Drugs</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>79</volume><issue>4</issue><spage>381</spage><epage>400</epage><pages>381-400</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><abstract>Prostate cancer (PC) is a major health issue in developed countries, with, on the one hand, men suffering from sequelae related to unnecessary treatment of non-lethal PC, and, on the other hand, still dying because of advanced PC that progresses to castration-resistant disease. Systemic treatment is the mainstay of therapy of castration-resistant PC (CRPC). To date, a multitude of systemic agents have been tested and many of these have failed to provide a clinically meaningful benefit in CRPC, while others have been approved by the US Food and Drug Administration and/or the European Medicines Agency, including antiandrogen hormonal drugs (abiraterone, enzalutamide, apalutamide), chemotherapy (docetaxel and cabazitaxel), immunotherapy (Sipuleucel-T), and radiopharmaceutical (Radium-223) agents. In this review, systemic treatments regarded as most likely to have an impact in clinical practice are presented and discussed. In addition to the pivotal clinical studies, selected retrospective and non-randomized clinical trials are also discussed if deemed to have an impact on clinical practice or future research. A comprehensive appraisal of the expanding landscape of systemic therapies for advanced PC is provided from an expert perspective, with a focus on novel classification and diagnostic tools that have been paving the way for the development of precision medicine in PC.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>30742279</pmid><doi>10.1007/s40265-019-1060-5</doi><tpages>20</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2019-03, Vol.79 (4), p.381-400 |
| issn | 0012-6667 1179-1950 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2194157430 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Androgen Antagonists - therapeutic use Androgens Androstenes - therapeutic use Antineoplastic Agents - therapeutic use Antineoplastic Agents, Hormonal - therapeutic use Cancer therapies Castration Chemotherapy Clinical medicine Clinical trials Clinical Trials as Topic Complications Developed countries Diagnostic software Diagnostic systems Docetaxel - therapeutic use FDA approval Humans Immunotherapy Immunotherapy - methods Internal Medicine Landscape Male Medical research Medical treatment Medicine Medicine & Public Health Metastasis Molecular Targeted Therapy Pain Pharmaceuticals Pharmacology/Toxicology Pharmacotherapy Phenylthiohydantoin - analogs & derivatives Phenylthiohydantoin - therapeutic use Precision medicine Prostate cancer Prostatic Neoplasms - drug therapy Radiochemistry Radioisotopes Radiopharmaceuticals - therapeutic use Radium Radium - therapeutic use Retrospective Studies Review Article Taxoids - therapeutic use Thiohydantoins - therapeutic use Tissue Extracts - therapeutic use |
| title | The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T16%3A42%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Evolving%20Systemic%20Treatment%20Landscape%20for%20Patients%20with%20Advanced%20Prostate%20Cancer&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=Pagliuca,%20Martina&rft.date=2019-03-01&rft.volume=79&rft.issue=4&rft.spage=381&rft.epage=400&rft.pages=381-400&rft.issn=0012-6667&rft.eissn=1179-1950&rft_id=info:doi/10.1007/s40265-019-1060-5&rft_dat=%3Cproquest_cross%3E2194157430%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2258090566&rft_id=info:pmid/30742279&rfr_iscdi=true |